ライフサイエンスコーパス: unrelated donor

1 56) with recurrent disease after alloSCT (11 unrelated donors).

2 e with sibling donors and 64% for those with unrelated donors).

3 d unrelated donors, and 104 [11%] mismatched unrelated donors).

4 ograft came from a matched sibling versus an unrelated donor.

5 nor, and many patients do not have a matched unrelated donor.

6 indicated but who lack a matched related or unrelated donor.

7 ed donor, either a sibling (>40-50 years) or unrelated donor.

8 from an HLA-identical sibling and 40 from an unrelated donor.

9 loablative allogeneic procedure involving an unrelated donor.

10 transplantation urgently or lack a 7-8 of 8 unrelated donor.

11 able to rapidly identify a suitably matched unrelated donor.

12 with a 12/12 human leukocyte antigen-matched unrelated donor.

13 sibling, 884 from a 7 or 8 of 8 HLA-matched unrelated donor.

14 y human leukocyte antigen-matched related or unrelated donor.

15 tical sibling or a partially or well-matched unrelated donor.

16 d received a kidney transplant from a living-unrelated donor.

17 rgoing HCT from a matched-related or matched-unrelated donor.

18 ceipt of a transplant from an HLA-mismatched unrelated donor.

19 re haemopoietic cell transplantation from an unrelated donor.

20 HLA-identical siblings or HLA allele-matched unrelated donors.

21 tic-cell transplants from matched related or unrelated donors.

22 FMT using frozen encapsulated inoculum from unrelated donors.

23 M were serious comorbidities and grafts from unrelated donors.

24 ly for patients with HLA-matched sibling and unrelated donors.

25 is comparable to that of matched related or unrelated donors.

26 ls (PBPCs) from 8 of 8 or 7 of 8 HLA-matched unrelated donors.

27 equent depression diagnosis among nonspousal unrelated donors.

28 aged 40 to 49 years; older cohorts had more unrelated donors.

29 em-cell and bone marrow transplantation from unrelated donors.

30 not correlate significantly with outcomes in unrelated donors.

31 ors, matched unrelated donors, or mismatched unrelated donors.

32 y-two patients had related donors and 34 had unrelated donors.

33 first from HLA-identical siblings and later unrelated donors.

34 and 52% of patients received stem cells from unrelated donors.

35 atched related donors and 39 had HLA-matched unrelated donors.

36 SCT using human leukocyte antigen-mismatched unrelated donors.

37 or umbilical cord blood (14%); 53% were from unrelated donors.

38 gs (n=5), and matched (9) and mismatched (2) unrelated donors.

39 results of transplantation from HLA-matched unrelated donors.

40 atopoietic-cell transplants from related and unrelated donors.

41 ients of hematopoietic-cell transplants from unrelated donors.

42 , and 38% of patients had matched/mismatched unrelated donors.

43 of hematopoietic-cell transplants and their unrelated donors.

44 (1.5%) mismatch related, and 4 (6%) mismatch unrelated donors.

45 received blended homogenized stool from 3-7 unrelated donors.

46 24-72) after transplantation from mismatched unrelated donors.

47 underwent HCT from 9/10 or 10/10 HLA-matched unrelated donors.

48 followed by HCT from HLA-matched related or unrelated donors.

49 haemopoietic cell transplantation when using unrelated donors.

50 HLA match are important when selecting adult unrelated donors.

51 ed donors, and 31 (72%) received grafts from unrelated donors.

52 ized blood cells from HLA-matched related or unrelated donors.

53 e HLA locus received bone marrow grafts from unrelated donors.

54 rom HLA-matched, and 41% from HLA-mismatched unrelated donors.

55 nors (1.43, 0.81-2.50; p=0.21) or mismatched unrelated donors (1.17, 0.67-2.05; p=0.58) versus HLA-ma

56 donors (5.30, 3.17-8.86; p<0.0001), matched unrelated donors (3.71, 2.39-5.75; p<0.0001), and mismat

57 d-blood donor (140 patients), an HLA-matched unrelated donor (344), or an HLA-mismatched unrelated do

58 (3.71, 2.39-5.75; p<0.0001), and mismatched unrelated donors (4.34, 2.58-7.32; p<0.0001) than in pat

59 m HLA-matched siblings (40%) or well-matched unrelated donors (48%).

60 th related donors (79% vs 39%; P = .001) and unrelated donors (53% vs 26%; P < .001).

61 nts, 7 received HSCT from related and 4 from unrelated donors; 9 patients received busulfan-based con

62 unrelated donor (344), or an HLA-mismatched unrelated donor (98).

63 utcomes in 390 US patients and their matched unrelated donors, accrued between 1995 and 2004.

64 ived HCT from an HLA-identical sibling or an unrelated donor after intravenous busulfan plus cyclopho

65 Allogeneic HCT from related or unrelated donors after conditioning with low-dose TBI an

66 We examined current outcomes of unrelated donor allogeneic hematopoietic cell transplant

67 l grafts were associated with survival after unrelated-donor allogeneic hematopoietic stem-cell trans

68 ative human leucocyte antigen (HLA)-matched, unrelated donor, allogeneic haemopoietic stem cell trans

69 patients received bone marrow grafts from an unrelated donor and a myeloablative conditioning regimen

70 a haploidentical relative or HLA-mismatched unrelated donor and patients age 13 years or older with

71 receipt of a transplant from an HLA-matched unrelated donor and was significantly higher than the pr

72 rtunities for LDKTx, centers may accept more unrelated donors and adopt programs to overcome biologic

73 ce-based guidelines for optimal selection of unrelated donors and cord blood units.

74 acilitated by the increasing availability of unrelated donors and cord blood, and the inclusion of ol

75 e Bu-Flu patients were older, more often had unrelated donors and had a shorter follow-up.

76 ematopoietic cell transplantation (HCT) from unrelated donors and in the setting of solid organ trans

77 f matched sibling donors followed by matched unrelated donors and then other donors holds.

78 ajority (52%) received transplantations from unrelated donors and were given antithymocyte globulin f

79 We obtained blood from healthy unrelated donors and, using a panel of 45 alpha3(IV)NC1

80 oidentical related donors, 111 [12%] matched unrelated donors, and 104 [11%] mismatched unrelated don

81 or mismatched family donor, 3.97% in matched unrelated donors, and 11.24% in mismatched unrelated don

82 elated donors, 2 received PBSCs from matched-unrelated donors, and 2 received stem cells from umbilic

83 3-60) after transplantation from HLA-matched unrelated donors, and 47 months (24-72) after transplant

84 ction and limit of quantitation of 0.15% for unrelated donors, and limit of blank of 0.23%, a limit o

85 and more comorbidities, more frequently had unrelated donors, and more often had malignancy in remis

86 ematopoietic cell transplantation (HCT) from unrelated donors as compared with related donors.

87 (9)/L before transplantation, HLA-mismatched unrelated donor, ASXL1 mutation, and non-CALR/MPL driver

88 Conclusions and Relevance: Recipients of unrelated donor BM had better psychological well-being,

89 partially matched sibling BM or PB (n = 24), unrelated donor BM or PB (n = 313), single (n = 89) or d

90 Interventions: Unrelated donor BM or PB hematopoietic cell transplantat

91 Outcome after unrelated donor bone marrow (BM) transplantation for sev

92 n a multicenter randomized clinical trial of unrelated donor bone marrow (BM) vs peripheral blood (PB

93 gnostic factors that influence outcome after unrelated donor bone marrow transplantation in children

94 pse are long-term survivors, suggesting that unrelated donor bone marrow transplantation is an effect

95 er haemopoietic cell transplantation from an unrelated donor, but evidence of patient benefit is abse

96 ffect were age >/= 50 years, female sex, and unrelated donor, but not the intensity of the conditioni

97 For patients lacking a matched family donor, unrelated donors can be readily found, although mostly f

98 Transplantation of hematopoietic cells from unrelated donors can cure blood disorders but carries a

99 therapy followed by allo-SCT from related or unrelated donors can provide durable remission even in e

100 (P = .03), but not for recipients of younger unrelated donor CD8(lo) grafts (P = .28).

101 relapsing CDI using a frozen suspension from unrelated donors, comparing colonoscopic and nasogastric

102 Use of unrelated donor cord blood (CB) as an alternative stem c

103 Unrelated donor cord blood transplantation from partiall

104 Outcomes of unrelated donor cord blood transplantation in 191 hemato

105 rgoing LDKTx at centers with greater use of "unrelated donors" (defined as nonspouses and nonfirst-de

106 Using PBSCs from unrelated donors does not appear to be more beneficial t

107 leukocyte antigen-matched sibling or from an unrelated donor during the years 2000 to 2006 for acute

108 to 40 years and 165% [corrected] increase in unrelated donors for alloHCT, overall survival (OS) at d

109 n of hematopoietic stem cells (HSCs) from an unrelated donor, frequently residing in another country,

110 nofsky score of at least 60, and received an unrelated donor (fully matched or one-locus mismatched a

111 In this study of 936 patients who had unrelated donors, genotypes of single nucleotide polymor

112 erval from diagnosis to transplantation, and unrelated donor grafts adversely affected OS in multivar

113 gnificantly better for recipients of younger unrelated donor grafts with CD8(hi) doses (P = .03), but

114 2 and 10% of patients receiving related and unrelated donor grafts.

115 Seronegative patients receiving seropositive unrelated-donor grafts had decreased overall survival (h

116 to 55%) and 50% (95% CI, 38% to 64%) for the unrelated donor group.

117 tween the cord-blood group and the two other unrelated-donor groups appeared to vary according to the

118 disease was significantly higher in the two unrelated-donor groups than in the cord-blood group (haz

119 patients receiving grafts from seropositive unrelated donors had improved overall survival (HR, 0.92

120 Patients with HLA-matched related or unrelated donors had similar survivals.

121 alternative donors such as mismatched adult unrelated donors, haploidentical related donors, and umb

122 Umbilical cord blood transplantation from unrelated donors has been previously shown to improve ne

123 older patients and the more frequent use of unrelated donors has led to increased numbers of patient

124 mobilized peripheral blood from related and unrelated donors has yet to be established.

125 ve case-series of 482 patients who underwent unrelated donor HCT (2005-2013) with T/S-based GvHD prop

126 analyzed data from 2062 patients undergoing unrelated donor HCT for acute myeloid leukemia (AML; n =

127 oning regimens before a related or volunteer-unrelated donor HCT for refractory acute myeloid leukaem

128 of pretransplantation DSAs in recipients of unrelated donor HCT is associated with failed engraftmen

129 A, -B, -C, and -DRB1 is required for optimal unrelated donor HCT survival, and avoidance of nonpermis

130 were tested to evaluate the role of DSAs in unrelated donor HCT.

131 s much as 80% of all patients who receive an unrelated donor hematopoietic cell transplant (HCT) for

132 igh risk of nonrelapse mortality (NRM) after unrelated donor hematopoietic cell transplant (HCT).

133 itive), we studied PBMCs obtained 6 mo after unrelated donor hematopoietic cell transplantation (HCT)

134 These interactions affect the outcome of unrelated donor hematopoietic cell transplantation (HCT)

135 inform donor selection to improve outcome of unrelated donor hematopoietic cell transplantation for a

136 atening risks associated with HLA-mismatched unrelated donor hematopoietic cell transplantation limit

137 aimed at externally validating this model in unrelated donor hematopoietic cell transplantation.

138 ated SNPs and adverse outcomes after matched unrelated donor hematopoietic cell transplantations in U

139 M) loci on the outcome of 2687 myeloablative unrelated donor hematopoietic cell transplantations perf

140 pid adoption of treatment strategies such as unrelated donor hematopoietic stem cell transplant and t

141 nd 299 patients in CR2 in undergoing matched unrelated donor hematopoietic stem cell transplantation

142 TRM) and should be avoided to secure optimal unrelated donor hematopoietic stem cell transplantations

143 reactivation on T-cell reconstitution after unrelated-donor hematopoietic stem cell transplant.

144 or chimerism, all 3 recipients of mismatched unrelated donor HSCT had high levels of donor T-cell chi

145 Unrelated donor HSCT recipients were at greatest risk.

146 identical sibling or a 10/10 allelic-matched unrelated donor in the same period.

147 fferences in the HLA alleles of patients and unrelated donors in hematopoietic stem cell transplantat

148 se (GVHD) limits the use of HLA-C-mismatched unrelated donors in transplantation.

149 We aim to use matched related and unrelated donors (including cord blood) whenever possibl

150 ore resources, more transplant teams, and an unrelated donor infrastructure.

151 or sources when a matched related or matched unrelated donor is not available.

152 marrow, especially when an HLA-matched adult unrelated donor is not available.

153 ct on overall survival if a CMV-seropositive unrelated donor is selected for a CMV-seronegative patie

154 lity study, FMT using a frozen inoculum from unrelated donors is effective in treating relapsing CDI.

155 In conclusion, PBSC collection in unrelated donors is generally safe, but nearly all donor

156 D), but the safety and efficacy of HSCT from unrelated donors is less certain.

157 Among unrelated donors <35, 35-49, and >=50, white donors incr

158 The optimum preparative regimen for unrelated donor marrow transplantation in patients with

159 ng either BM (n = 225) or PBPC (n = 71) from unrelated donors matched at human leukocyte antigen-A, -

160 ved hematopoietic stem-cell transplants from unrelated donors matched for HLA-A, B, C, DR, and DQ or

161 rtance: Bone marrow or peripheral blood from unrelated donors may be used for hematopoietic cell tran

162 ntical (haplo)-related donor, and mismatched unrelated donor (MMUD) are available.

163 ot available, a haploidentical or mismatched unrelated donor (mMUD) can be useful.

164 HLA-mismatched unrelated donor (MMUD) hematopoietic stem-cell transplan

165 term outcome in matched (MUD) and mismatched unrelated donor (mMUD) setting is not well defined.

166 phylaxis in patients undergoing a mismatched unrelated donor (MMUD) transplant.

167 g HSCT from an MRD (n = 4) or an HLA-matched unrelated donor (MUD) (n = 7); 9 children were boys, and

168 s younger than 40-50 years, with HLA-matched unrelated donor (MUD) HSCT for second line after failure

169 For the remaining patients, a matched unrelated donor (MUD) is an alternative.

170 with a younger allele-level 8/8 HLA-matched unrelated donor (MUD) rather than an older HLA-matched s

171 ing alloHSCT with a sibling (sib) or matched unrelated donor (MUD) to patients younger than 55 years

172 the development of graft failure in matched unrelated donor (MUD) transplantation remains unclear.

173 o hundred patients were grafted from matched unrelated donor (MUD), of these, 129 (64.5%) received an

174 -matched sibling donor (SIB) and HLA-matched unrelated donor (MUD).

175 a male human leukocyte antigen (HLA)-matched unrelated donor (MUD, 8/8, n=2,014) might be an alternat

176 ted donor (MRD, n = 204), HLA allele-matched unrelated donor (MUD, n = 152) or 1-antigen-mismatched u

177 a matched related (MRD, n = 29) or a matched unrelated donor (MUD, n = 3), 20 to autoHSCT in CR1 and

178 HLA) matched related donor (MRD) and matched unrelated donors (MUD) produces similar survival for pat

179 h TCRalphabeta+/CD19+ depletion from matched unrelated donors (MUDs) and mismatched related donors (M

180 atched sibling donors (MRDs) and HLA-matched unrelated donors (MUDs).

181 m matched related donors (MRDs, 56), matched unrelated donors (MUDs, 66), or HLA-mismatched donors (3

182 haploidentical (n = 192) and 8/8 HLA-matched unrelated donor (n = 1982) transplantation.

183 cell transplantation from related (n = 9) or unrelated donors (n = 15) in 15 institutions worldwide w

184 were matched unrelated donors or mismatched unrelated donors (n = 18) and matched related donors (n

185 hematopoietic cells from related (n = 45) or unrelated donors (n = 2).

186 ed transplantations from sibling (n = 11) or unrelated donors (n = 23) between 2003 and 2009.

187 ) as a preparative regimen and patients with unrelated donors (n = 34) receiving conditioning with Fl

188 atched unrelated donors (n = 72), mismatched unrelated donors (n = 37), matched sibling donors (n = 1

189 Donors were matched unrelated donors (n = 72), mismatched unrelated donors (

190 tween 1990 and 2009 from related (n = 86) or unrelated donors (n = 84).

191 Among recipients of transplantations from unrelated donors, no significant differences in event-fr

192 eles in patients and their 10/10 HLA-matched unrelated donors of 379 HCTs performed at our center for

193 leukocyte antigen-identical sibling or match unrelated donor options.

194 an 5 years of age, no suitable 10/10 matched unrelated donor or 6/6 unrelated cord blood donor.

195 ation of reconstituting NK cells after adult unrelated donor or umbilical cord blood grafting.

196 Stem cell donors were matched unrelated donors or mismatched unrelated donors (n = 18)

197 LDTR quartiles were also more likely to use "unrelated" donors (OR 8.30 per tertile of higher use; P<

198 (1.17, 0.67-2.05; p=0.58) versus HLA-matched unrelated donors, or mismatched unrelated donors versus

199 nors, haploidentical related donors, matched unrelated donors, or mismatched unrelated donors.

200 3; 95% CI, 1.13 to 1.79; P = .01), use of an unrelated donor (P = .03), and RIC (HR, 0.79; 95% CI, 0.

201 We report outcomes of 932 recipients of unrelated donor peripheral blood stem cell hematopoietic

202 replaced bone marrow (BM) as the most common unrelated donor progenitor cell product collected, a dir

203 This article reviews aspects of the Living Unrelated Donor program and development of deceased dona

204 Recipients of matched-related and -unrelated donors received fludarabine and 200 cGy of tot

205 extensively human leukocyte antigen-matched, unrelated donor-recipient pairs by using multivariate Co

206 association with the risk of chronic GVHD in unrelated donor-recipient pairs from 1 cohort, but none

207 e associations was replicated when tested in unrelated donor-recipient pairs from an independent coho

208 fraction was quantified in both related and unrelated donor-recipient pairs.

209 in related donor-recipient pairs but not in unrelated donor-recipient pairs.

210 In addition to mismatch at minor H loci, unrelated donor/recipient pairs exhibit genetic disparit

211 Although the 8 matched related or unrelated donor recipients had full donor chimerism, all

212 Matched unrelated donor recipients showed a 3.8-fold elevated ri

213 d unrelated donors, and 11.24% in mismatched unrelated donor recipients.

214 5%) living-related versus none of the living-unrelated donors' recipients recurred.

215 Use of unrelated donors, reduced-intensity conditioning and the

216 The development of unrelated donor registries and increased utilization of

217 Unrelated donor registries contributed 22.3 million type

218 eukocyte antigen (HLA)-matched family donor, unrelated donor registries of adult volunteers and banke

219 ithout a suitable related HLA-matched donor, unrelated-donor registries of adult volunteers and banke

220 lodysplastic syndrome, and their HLA-matched unrelated donors, reported to the Center for Internation

221 ts, allogeneic HSCT from matched related and unrelated donors resulted in a limited improvement of ov

222 and provides guidance and regulations about unrelated donor safety and care.

223 Prospective typing of patients and donors in unrelated donor search may identify mismatches for MICA-

224 typing of several best HLA-matched potential unrelated donors should substantially increase the frequ

225 trials and a recently completed trial using unrelated donor stem cells has been reported.

226 ral-blood stem cells versus bone marrow from unrelated donors to compare 2-year survival probabilitie

227 s) in 2628 patients and their HLA-mismatched unrelated donors to determine whether SNPs are associate

228 conditioning followed by a matched 10 of 10 unrelated donor transplant from BM or peripheral blood s

229 Matched unrelated donor transplant recipients received CNI with

230 e-matched (at HLA-A, -B, -C, and -DRB1 loci) unrelated donor transplant.

231 of human leukocyte antigen (HLA) matching in unrelated donor transplantation for nonmalignant disease

232 ociated with significant organ toxicity) for unrelated donor transplantation for severe aplastic anae

233 tive conditioning and few early deaths after unrelated donor transplantation for severe aplastic anae

234 D in the setting of HLA-identical sibling or unrelated donor transplantation in adult patients with h

235 te that BM is the preferred graft source for unrelated donor transplantation in SAA.

236 Outcome after HLA-mismatched unrelated donor transplantation is influenced by MHC reg

237 The immunogenicity of HLA-C mismatches in unrelated donor transplantation is influenced by the exp

238 Among unrelated donor transplantation recipients, the RRs for

239 Optimizing the results of unrelated donor transplantation requires an understandin

240 A total of 236 recipients of unrelated donor transplantation were studied.

241 te lymphoblastic leukemia who are undergoing unrelated donor transplantation with myeloablative total

242 in 87 transplant pairs that received matched unrelated donor transplantation, especially for RFS (P=0

243 otal body irradiation-based conditioning and unrelated donor transplantation, in the present study, w

244 dard GVHD prophylaxis in patients undergoing unrelated donor transplantation, including decreases in

245 relatively higher risk: patients undergoing unrelated donor transplantation, receiving TBI, and thos

246 used and produces similar results to matched unrelated donor transplantation.

247 settings, when used in matched, related, and unrelated donor transplantation.

248 y are matched has not been fully defined for unrelated donor transplantation.

249 ith haematological malignancies selected for unrelated donor transplantation.

250 randomized to receive 1 of 2 graft types for unrelated donor transplantation.

251 cyclophosphamide is comparable with matched unrelated donor transplantation.

252 elated, HLA-matched unrelated, or mismatched unrelated donor transplantation.

253 registered adult donors, and the numbers of unrelated donor transplantations are increasing.

254 s 15% at 4 years (8% for sibling and 22% for unrelated donor transplantations), acute grade 2 or 3 gr

255 r after haploidentical compared with matched unrelated donor transplants (90% vs 97%, P = .02).

256 CI, 47-53) after haploidentical and matched unrelated donor transplants (P = .38).

257 associated with deleterious effects in 3853 unrelated donor transplants stratified according to numb

258 oes not significant affect these outcomes in unrelated donor transplants suggesting that the strength

259 811 HLA-matched sibling (61%) and 522 (39%) unrelated donor transplants.

260 r after haploidentical compared with matched unrelated donor transplants.

261 HLA-matched related-donor and 35 HLA-matched unrelated-donor transplants were done.

262 similar at 81%, 66% after 10/10 HLA-matched unrelated donor (UD), and 68% after 5/6 matched CB donor

263 rom matched sibling donors (MSD; n = 21) and unrelated donors (UD; n = 29), using fludarabine 30 mg/m

264 etic cell transplantation (HCT), sibling and unrelated donors (UDs) are biologically different becaus

265 oietic stem cell transplantation (HSCT) with unrelated donors (UDs) showed no association between the

266 rs were matched family donors (MFDs; n = 6), unrelated donors (UDs; n = 12), and haploidentical donor

267 myelomonocytic leukemia, given single-unit, unrelated donor umbilical cord blood transplantation.

268 ransplantation with partially HLA-mismatched unrelated donor umbilical cord blood were studied to inv

269 hed related-donor transplantation (MMRDT) or unrelated-donor umbilical cord blood transplantation (UC

270 For patients lacking a suitable family or unrelated donor, umbilical cord blood provides a promisi

271 nt-related mortality (TRM) and relapse after unrelated donor (URD) hematopoietic cell transplantation

272 antation of hematopoietic stem cells from an unrelated donor (URD) is an option for many patients who

273 ived haploidentical (n = 185) or HLA-matched unrelated donor (URD) transplantation either with (n = 2

274 is review summarizes the state of the art of unrelated donor (URD) umbilical cord blood transplantati

275 al risk that use myeloablative conditioning, unrelated donor (URD), and methotrexate are not known.

276 syndrome, transplanted from related donors, unrelated donors (URD), or unrelated cord blood between

277 chemotherapy-based conditioning from matched unrelated donors (URDs), either from volunteer adults or

278 with unfavorable cytogenetics using matched unrelated donors (URDs).

279 -identical sibling donors (SDs; n = 3191) or unrelated donors (URDs; n = 2370) and reported to the Ce

280 ary importance in transplantation with adult unrelated donors, using conventional graft-versus-host d

281 HLA-matched unrelated donors, or mismatched unrelated donors versus haploidentical related donors (1

282 GVHD was more common in matched unrelated donor vs matched sibling donor recipients and

283 ifference in eGFR slopes between related and unrelated donors was 0.20 mL/min/1.753 m(2) /year (0.07-

284 age 12 years or younger with an HLA-matched unrelated donor were at intermediate risk (3-year EFS, 8

285 ts age 13 years or older with an HLA-matched unrelated donor were high risk (3-year EFS, 57%; score,

286 -HSCT, and with an HLA-compatible related or unrelated donor were randomly assigned to myeloablative

287 ions of transplants from matched siblings or unrelated donors were 54% and 46%.

288 ecent years, and from HLA-matched related or unrelated donors were associated with a significantly be

289 ior relapse resistant to therapy, and use of unrelated donors were associated with higher NRM.

290 lthy first-degree relatives, and 141 healthy unrelated donors were measured for IFNalpha activity usi

291 Nine unrelated donors were mismatched for >/= one HLA antigen

292 rd blood transplants and marrow from matched unrelated donors were similar (31%, 95% CI 27-35 and 32%

293 ated-donors or HLA-9/10 or HLA-10/10 matched unrelated-donors were infused.

294 a, and 10 Diamond-Blackfan anemia) and their unrelated donors who had pre-HCT blood samples and clini

295 A-genoidentical siblings or from HLA-matched unrelated donors who were identified and matched by high

296 A search for an unrelated donor will be undertaken for patients without

297 Whether the same benefits accrue from unrelated donors will require further follow-up.

298 is an effective therapy, whereas AHSCT from unrelated donors with FluMel/ATG conditioning led to a h

299 This analysis demonstrates that unrelated donors with KIR B haplotypes confer significan

300 transplants from HLA-A,B,C,DRB1,DQB1-matched unrelated donors with only one HLA-DPB1 mismatch, linkag